Revascularization

MRG-110     Actively Recruiting Healthy Volunteers in the United States for Dermal Revascularization

➤ A Phase 1 clinical trial, MRG110-01-001, designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of MRG-110 following local intradermal injection after skin excisional wound creation in normal healthy volunteers.

MRG-110 is intended to promote the growth of new blood vessels by inhibiting a molecule called miR-92a. MRG-110 is being studied to determine if it can accelerate healing of wounds by improving blood flow into the wound area.

Participants in the clinical trial will receive either a single dose or multiple doses of MRG-110 and/or placebo. Blood samples, urine samples and skin biopsies will be collected to measure how MRG-110 is processed by the body, and how the body responds when exposed to MRG-110.

More information on this study can be found here.

More information about MRG-110 can be found here.


MRG-110     Actively Recruiting Healthy Volunteers in Belgium for Cardiac Revascularization *Partnered with Servier

➤ A phase 1 clinical trial, CL1-95010-001, designed to investigate the safety, tolerability and pharmacokinetics of S95010 after single escalating intravenous doses in young healthy male subjects.

More information on this study can be found here.

More information about MRG-110 can be found here.